No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Adynovate is a hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is a recombinant factor VIII (FVIII) therapy, which is a type of protein replacement therapy. Adynovate is designed to reduce the frequency of bleeding episodes and to improve the quality of life of people with hemophilia A. It is administered via intravenous injection and is available in both a single-dose vial and a multi-dose vial.
Adynovate is a relatively new drug in the hematological drug market, having been approved by the US Food and Drug Administration (FDA) in 2018. It is the first and only FVIII therapy to be approved for both on-demand and prophylactic use in adults and children with hemophilia A.
The Adynovate market is highly competitive, with several other FVIII therapies available. These include Advate, Eloctate, Kogenate, and Xyntha. All of these therapies are designed to reduce the frequency of bleeding episodes and improve the quality of life of people with hemophilia A.
Some of the companies in the Adynovate market include Pfizer, Novo Nordisk, Shire, and Bayer. These companies are all major players in the hematological drug market, and they all produce FVIII therapies for Show Less Read more
